Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Overview of attention for article published in New England Journal of Medicine, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 76 news stories from 57 outlets.

Peter Mohr, MD The European Commission has approved single-agent nivolumab (Opdivo) for use in the adjuvant treatment of adult…

This transcript has been edited for clarity. I'm Dr Jeffrey Weber, medical oncologist at the Laura and Isaac Perlmutter Cancer…

Im Onko-Blog dieser Woche berichten wir, dass möglicherweise eine nur systemische Therapie des metastasierten…

There is still a great deal to learn about the optimal use of BRAF-targeted therapy, as well as immunotherapy, in the adjuvant…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 72 additional news stories.